Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial
Journal of Clinical Oncology · 10.04.2026 · 44 (11) · 959-969
DOI: 10.1200/jco-25-01796 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2026. Verfasst von Hai-Dong Zhu und 30 weiteren Autor:innen. Beteiligte Einrichtung: Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Transarterial chemoembolization (TACE) alone has shown limited efficacy in improving survival among patients with unresectable hepatocellular carcinoma (HCC). This phase II trial compared TACE combined with camrelizumab (anti–PD-1 antibody) and rivoceranib (vascular endothelial growth factor receptor 2 inhibitor) versus TACE in unresectable HCC. METHODS Patients with unresectable HCC (Barcelona Clinic Liver Cancer stage A to C without extrahepatic metastases) and Child-Pugh class A liver function were randomly assigned (1:1), stratified by macrovascular invasion, previous tyrosine kinase inhibitor treatment, and number of previous TACE procedures, to receive TACE combined with camrelizumab (200 mg once every 3 weeks) and rivoceranib (250 mg once daily; TACE-C-R) or TACE alone. The primary end point was progression-free survival (PFS) per composite criteria (progression per Response Evaluation Criteria in Cancer of the Liver version 5, transient deterioration to Child-Pugh class C, or TACE failure or refractoriness) in the intention-to-treat population. RESULTS Between December 28, 2020, and October 29, 2023, 200 patients were randomly assigned (100 in each group). Median PFS per composite criteria was significantly longer with TACE-C-R than with TACE (10.8 months [95% CI, 8.8 to 13.7] v 3.2 months [95% CI, 2.4 to 4.2]; hazard ratio, 0.34 [95% CI, 0.24 to 0.50], P < .001). Grade ≥3 treatment-related adverse events occurred in 74.5% (70 of 94) of patients with TACE-C-R and 22.3% (23 of 103) of patients with TACE, with the most common being increased AST (29 [30.9%] and 13 [12.6%]) and increased ALT (23 [24.5%] and 14 [13.6%]). CONCLUSION The addition of camrelizumab and rivoceranib to TACE showed statistically significant improvement in PFS for patients with unresectable HCC, with a manageable safety profile. Follow-up for further overall survival analysis is ongoing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
- National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University), Southeast University, Nanjing, China.
- Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of Interventional Therapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
- Department of Interventional Radiology, Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of Intervention Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
ORCID-Profile: Zhi-Cheng Jin, Yong-Yi Zeng, Yuan-Cheng Wang, Gao-Jun Teng
Zitieren
APA
Zhu, H. D., Fan, W. J., Zhao, C., Wang, S., Li, Y. L., Jin, Z. C., Zhang, Z. W., Guo, J. H., Cheng, H. T., Zhang, Q., Lu, J., Zeng, Y. Y., Lv, W. F., Xu, H., Shao, H. B., Xu, W. G., Zhao, X. Y., Gu, S. Z., Lin, H. L., …, & Teng, G. J. (2026). Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. Journal of Clinical Oncology, 44(11), 959-969. https://doi.org/10.1200/jco-25-01796
Vancouver
Zhu HD, Fan WJ, Zhao C, Wang S, Li YL, Jin ZC, et al. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. Journal of Clinical Oncology. 2026;44(11):959-969. doi:10.1200/jco-25-01796
BibTeX
@article{Zhu2026,
author = {Zhu, Hai-Dong and Fan, Wei-Jun and Zhao, Chang and Wang, Song and Li, Yu-Liang and Jin, Zhi-Cheng and Zhang, Zhe-Wei and Guo, Jin-He and Cheng, Hong-Tao and Zhang, Qi and Lu, Jian and Zeng, Yong-Yi and Lv, Wei-Fu and Xu, Hao and Shao, Hai-Bo and Xu, Wei-Guo and Zhao, Xu-Ya and Gu, Shan-Zhi and Lin, Hai-Lan and Zheng, Wen-Heng and Piao, Long-Zhen and Song, Yu-Sheng and Zhao, Jian-Bo and Wang, Yuan-Cheng and Hou, Zhi-Guo and Sun, Ying and Guan, Ni and Huang, Ming and Yang, Wei-Zhu and Ji, Jian-Song and Teng, Gao-Jun},
title = {Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {11},
pages = {959--969},
doi = {10.1200/jco-25-01796}
}
EUVIMED